Search results
Showing 16 to 30 of 314 results for breast cancer
condition Cancer Lynch syndrome: should I take aspirin to reduce my chance of getting bowel cancer? Medicines to reduce the...
NICE is unable to make a recommendation on sacituzumab govitecan (Trodelvy) for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1089
Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.
Show all sections
Thousands more breast cancer patients to benefit from new NHS treatment
NICE approves ribociclib combination therapy to help prevent cancer returning in early-stage disease.
This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.
Evidence-based recommendations on capivasertib (Truqap) with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment in adults.
Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)
Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.
Early and locally advanced breast cancer: diagnosis and management (NG101)
This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.
Thousands of people a year could benefit from new twice-a-day tablet for advanced breast cancer
We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately through the Cancer Drugs Fund.
Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non-small-cell lung cancer after complete tumour resection in adults.
Show all sections
This guideline covers care and support for people with advanced (stage 4) breast cancer. It aims to help them and their healthcare professionals make shared decisions about tests and treatments to improve outcomes and quality of life.
Evidence-based recommendations on olaparib (Lynparza) for BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy in adults.
View recommendations for TA1040Show all sections
Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Show all sections
We have also recommended osimertinib for routine use on the NHS today.